Asset Details
Do you wish to reserve the book?
Production of adeno-associated virus vectors for in vitro and in vivo applications
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Production of adeno-associated virus vectors for in vitro and in vivo applications
Do you wish to request the book?
Production of adeno-associated virus vectors for in vitro and in vivo applications
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Production of adeno-associated virus vectors for in vitro and in vivo applications
2019
Overview
Delivering and expressing a gene of interest in cells or living animals has become a pivotal technique in biomedical research and gene therapy. Among viral delivery systems, adeno-associated viruses (AAVs) are relatively safe and demonstrate high gene transfer efficiency, low immunogenicity, stable long-term expression, and selective tissue tropism. Combined with modern gene technologies, such as cell-specific promoters, the Cre/lox system, and genome editing, AAVs represent a practical, rapid, and economical alternative to conditional knockout and transgenic mouse models. However, major obstacles remain for widespread AAV utilization, such as impractical purification strategies and low viral quantities. Here, we report an improved protocol to produce serotype-independent purified AAVs economically. Using a helper-free AAV system, we purified AAVs from HEK293T cell lysates and medium by polyethylene glycol precipitation with subsequent aqueous two-phase partitioning. Furthermore, we then implemented an iodixanol gradient purification, which resulted in preparations with purities adequate for
in vivo
use. Of note, we achieved titers of 10
10
–10
11
viral genome copies per µl with a typical production volume of up to 1 ml while requiring five times less than the usual number of HEK293T cells used in standard protocols. For proof of concept, we verified
in vivo
transduction via Western blot, qPCR, luminescence, and immunohistochemistry. AAVs coding for glutaredoxin-1 (Glrx) shRNA successfully inhibited Glrx expression by ~66% in the liver and skeletal muscle. Our study provides an improved protocol for a more economical and efficient purified AAV preparation.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 13/89
/ 42/34
/ 631/1647
/ 64/60
/ 82/80
/ 96/106
/ 96/35
/ 96/44
/ Animals
/ Dependovirus - growth & development
/ Dependovirus - isolation & purification
/ Genomes
/ Glutaredoxins - antagonists & inhibitors
/ Humanities and Social Sciences
/ Humans
/ Lysates
/ Male
/ Muscle, Skeletal - metabolism
/ RNA, Small Interfering - genetics
/ Rodents
/ Science
/ Tropism
